)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Barinthus Biotherapeutics (BRNS) investor relations material
Barinthus Biotherapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Focus shifted to immunology and inflammation (I&I) pipeline, prioritizing VTP-1000 for celiac disease and deprioritizing infectious disease and oncology programs, with workforce reductions and resource reallocation announced in January 2025.
VTP-1000 Phase 1 AVALON trial progressing, with final SAD cohort dosed, MAD portion initiated in July 2025, and no treatment-related serious adverse events; SAD data expected early Q4 2025, MAD data mid-2026.
Completed Phase 1 trial of VTP-850 in prostate cancer, showing encouraging immunogenicity and no treatment-related SAEs.
Ongoing search for partners to continue development of VTP-300 for hepatitis B, VTP-850, and other viral vector assets; winding down CEPI-funded MERS program.
Corporate restructuring and pipeline prioritization ongoing.
Financial highlights
Net loss of $21.1 million for Q2 2025, up from $16.9 million in Q2 2024 and $19.7 million in Q1 2025; six-month net loss of $40.8 million, up from $32.5 million year-over-year.
Cash, cash equivalents, and restricted cash totaled $87.8 million as of June 30, 2025, down from $112.4 million at year-end 2024 and $100.6 million at March 31, 2025.
Revenue primarily from research incentives and grants; other operating income decreased due to reduced CEPI funding utilization.
Research and development expenses were $8.0 million in Q2 2025, down from $11.7 million in Q2 2024 and $8.3 million in Q1 2025, reflecting pipeline prioritization and workforce reduction.
General and administrative expenses increased to $15.4 million in Q2 2025 from $7.2 million in Q2 2024 and $12.6 million in Q1 2025, mainly due to $8.0 million in foreign exchange losses.
Outlook and guidance
Cash runway expected to fund operations and capital expenditures into early 2027, but continued losses and negative cash flows anticipated for the foreseeable future.
Additional funding may be required to advance pipeline and support commercialization; potential sources include equity, debt, or strategic partnerships.
R&D expenses for legacy infectious disease and oncology programs expected to decrease as trials complete; autoimmune program expenses to continue or increase.
SAD data from the AVALON trial expected early Q4 2025; MAD data anticipated mid-2026.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Barinthus Biotherapeutics earnings date
Q3 20254 Nov, 2025
Next Barinthus Biotherapeutics earnings date
Q3 20254 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Barinthus Biotherapeutics plc is a biotechnology company focused on the development of novel immunotherapies for infectious diseases and cancer. The company specializes in T-cell activating therapeutics and next-generation vaccine platforms designed to enhance immune response. The company is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage